The White House has held the first in a series of scheduled meetings with cannabis industry and research stakeholders to discuss a proposed new enforcement policy for CBD products.
Representatives of the Office of Information and Regulatory Affairs (OIRA) under the White House Office of Management and Budget (OMB) spoke with David Heldreth, CEO of Panacea Plant Sciences, on Wednesday to gain insight on the pending Food and Drug Administration (FDA) approach for cannabidiol.
Marijuana Moment caught up with Heldreth shortly after he finished attending the remote meeting, which is one of several discussions on the issue that OIRA scheduled after publishing a notice about its review of the FDA policy last month.
“Members of FDA were present but did not identify themselves besides the host. They opened the meeting with statements that they cannot reveal anything about the policy or when it will come out and essentially won’t provide any details,” he said. “Then they opened the floor for me.”
Heldreth said he raised questions about the legality of a new Centers for Medicare & Medicaid Services (CMS) initiative to cover certain hemp-derived CBD and THC products that launched on Wednesday.
“Current FDA policy is that CBD can’t be
Read full article on Marijuana Moment
